Advertisement
Screener

BioVie Inc. (BIVI) Stock-Based Compensation

2.8 / 5 stars · 68/120 Roast Me

BioVie Inc. Stock-Based Compensation

BioVie Inc. (BIVI) reported Stock-Based Compensation of $2.28 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-08-13.

Financial Statements › Cash Flow › Operating Activities

us-gaap:ShareBasedCompensation · last filed 2026-08-13

  • BioVie Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $256.72K, a 27.24% decline year-over-year.
  • BioVie Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $1.56M, a 361.38% increase year-over-year.
  • BioVie Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $197.34K, a 48.79% decline year-over-year.
  • BioVie Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $268.39K, a 125.73% increase year-over-year.
  • BioVie Inc. share-based payment arrangement, noncash expense for fiscal 2026 was $2.28M, a 91.04% increase from fiscal 2025.
  • BioVie Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $1.20M.
  • BioVie Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $4.22M, a 27.29% decline from fiscal 2022.
  • BioVie Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $5.81M, a 92.33% increase from fiscal 2021.
Period endShare-based Payment Arrangement, Noncash Expense 3 monthShare-based Payment Arrangement, Noncash Expense 4 monthShare-based Payment Arrangement, Noncash Expense 6 monthShare-based Payment Arrangement, Noncash Expense 9 monthShare-based Payment Arrangement, Noncash Expense 12 month
2026-06-30$256.72K
derived: 10-K 12 month − S-1/A 9 month · filed 2026-08-13
$1.82M
derived: sum of 2 quarters · filed 2026-08-13
$2.02M
derived: sum of 3 quarters · filed 2026-08-13
$2.28M
10-K · filed 2026-08-13
2026-03-31$1.56M
derived: S-1/A 9 month − 10-Q 6 month · filed 2026-08-06
$1.76M
derived: sum of 2 quarters · filed 2026-08-06
$2.03M
S-1/A · filed 2026-08-06
$2.38M
derived: sum of 4 quarters · filed 2026-08-13
2025-12-31$197.34K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-06
$465.72K
10-Q · filed 2026-02-06
$818.53K
derived: sum of 3 quarters · filed 2026-08-13
$1.16M
derived: sum of 4 quarters · filed 2026-08-13
2025-09-30$268.39K
10-Q · filed 2025-11-10
$621.20K
derived: sum of 2 quarters · filed 2026-08-13
$959.61K
derived: sum of 3 quarters · filed 2026-08-13
$1.34M
derived: sum of 4 quarters · filed 2026-08-13
2025-06-30$352.81K
derived: 10-K 12 month − S-1/A 9 month · filed 2026-08-13
$691.22K
derived: sum of 2 quarters · filed 2026-08-13
$1.08M
derived: sum of 3 quarters · filed 2026-08-13
$1.20M
10-K · filed 2026-08-13
2025-03-31$338.41K
derived: S-1/A 9 month − 10-Q 6 month · filed 2026-08-06
$723.74K
derived: sum of 2 quarters · filed 2026-08-06
$842.64K
S-1/A · filed 2026-08-06
$1.55M
derived: sum of 4 quarters · filed 2026-08-06
2024-12-31$385.33K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-06
$504.23K
10-Q · filed 2026-02-06
$1.21M
derived: sum of 3 quarters · filed 2026-08-06
$1.90M
derived: sum of 4 quarters · filed 2026-08-06
2024-09-30$118.90K
10-Q · filed 2025-11-10
$824.01K
derived: sum of 2 quarters · filed 2026-08-06
$1.51M
derived: sum of 3 quarters · filed 2026-08-06
$2.13M
derived: sum of 4 quarters · filed 2026-08-06
2024-06-30$705.12K
derived: S-1/A 12 month − 10-Q 9 month · filed 2026-08-06
$1.40M
derived: sum of 2 quarters · filed 2026-08-06
$2.02M
derived: sum of 3 quarters · filed 2026-08-06
$2.82M
S-1/A · filed 2026-08-06
2024-03-31$690.92K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-12
$1.31M
derived: sum of 2 quarters · filed 2025-05-12
$2.12M
10-Q · filed 2025-05-12
$2.86M
derived: sum of 4 quarters · filed 2025-05-12
2023-12-31$619.70K
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-11
$1.43M
10-Q · filed 2025-02-11
$2.17M
derived: sum of 3 quarters · filed 2025-02-11
$3.06M
derived: sum of 4 quarters · filed 2025-02-11
2023-09-30$808.03K
10-Q · filed 2024-11-13
$1.55M
derived: sum of 2 quarters · filed 2024-11-13
$2.44M
derived: sum of 3 quarters · filed 2024-11-13
$4.15M
derived: sum of 4 quarters · filed 2024-11-13
2023-06-30$742.42K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-30
$1.63M
derived: sum of 2 quarters · filed 2024-09-30
$3.34M
derived: sum of 3 quarters · filed 2024-09-30
$4.22M
10-K · filed 2024-09-30
2023-03-31$889.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-14
$2.60M
derived: sum of 2 quarters · filed 2024-05-14
$3.48M
10-Q · filed 2024-05-14
$5.28M
derived: sum of 4 quarters · filed 2024-05-14
2022-12-31$1.71M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-13
$2.59M
10-Q · filed 2024-02-13
$4.39M
derived: sum of 3 quarters · filed 2024-02-13
$5.32M
derived: sum of 4 quarters · filed 2024-02-13
2022-09-30$878.64K
10-Q · filed 2023-11-08
$2.68M
derived: sum of 2 quarters · filed 2023-11-08
$4.00M
10-Q · filed 2022-05-11
$4.76M
derived: sum of 4 quarters · filed 2023-11-08
2022-06-30$1.80M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-08-16
$2.73M
derived: sum of 2 quarters · filed 2023-08-16
$3.88M
derived: sum of 3 quarters · filed 2023-08-16
$5.81M
10-K · filed 2023-08-16
2022-03-31$930.33K
10-Q · filed 2022-05-11
$2.08M
derived: sum of 2 quarters · filed 2022-05-11
$4.00M
10-Q · filed 2023-05-12
$4.68M
derived: sum of 4 quarters · filed 2022-11-04
2021-12-31$1.15M
10-Q · filed 2022-05-11
$3.07M
10-Q · filed 2023-02-10
$3.75M
derived: sum of 3 quarters · filed 2022-11-04
$4.56M
derived: sum of 4 quarters · filed 2022-11-04
2021-09-30$1.93M
10-Q · filed 2022-11-04
$2.61M
derived: sum of 2 quarters · filed 2022-11-04
$2.34M
10-Q · filed 2022-05-11
$4.95M
derived: sum of 4 quarters · filed 2022-11-04
2021-06-30$679.28K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-27
$1.48M
derived: sum of 2 quarters · filed 2022-09-27
$3.02M
derived: sum of 3 quarters · filed 2022-09-27
$3.02M
10-K · filed 2022-09-27
2021-03-31$803.60K
10-Q · filed 2022-05-11
$2.34M
derived: sum of 2 quarters · filed 2022-05-11
$2.34M
10-Q · filed 2021-05-10
2020-12-31$1.54M
10-Q · filed 2022-05-11
$1.54M
10-Q · filed 2021-05-10
$1.54M
10-Q · filed 2022-02-08
2020-06-30$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2021-08-30
$13.68K
derived: sum of 2 quarters · filed 2021-08-30
$24.85K
derived: sum of 3 quarters · filed 2021-08-30
$24.85K
10-K · filed 2021-08-30
2020-03-31$13.68K
10-Q · filed 2021-05-10
$24.85K
derived: sum of 2 quarters · filed 2021-05-10
$24.85K
10-Q · filed 2021-05-10
2019-12-31$11.16K
10-Q · filed 2021-05-10
$11.16K
10-Q · filed 2021-01-29
2019-06-30$1.55K
derived: 10-K/A 12 month − 10-Q 9 month · filed 2020-08-07
$45.16K
derived: sum of 2 quarters · filed 2020-08-07
$61.45K
derived: sum of 3 quarters · filed 2020-08-07
$64.86K
10-K/A · filed 2020-08-07
2019-03-31$43.61K
10-Q · filed 2020-05-13
$59.89K
derived: sum of 2 quarters · filed 2020-05-13
$63.31K
10-Q · filed 2020-05-13
-$509.73K
derived: sum of 4 quarters · filed 2020-05-13
2018-12-31$16.29K
10-Q · filed 2020-05-13
$19.70K
10-Q · filed 2020-02-13
-$553.34K
derived: sum of 3 quarters · filed 2020-05-13
-$401.28K
derived: sum of 4 quarters · filed 2020-05-13
2018-09-30$3.41K
10-Q · filed 2020-05-13
-$569.63K
derived: sum of 2 quarters · filed 2020-05-13
-$417.56K
derived: sum of 3 quarters · filed 2020-05-13
-$390.54K
derived: sum of 4 quarters · filed 2020-05-13
2018-06-30-$573.04K
derived: 10-K 12 month − 10-Q 9 month · filed 2019-09-27
-$420.98K
derived: sum of 2 quarters · filed 2019-09-27
-$393.95K
derived: sum of 3 quarters · filed 2019-09-27
$238.16K
10-K · filed 2019-09-27
2018-03-31$152.06K
10-Q · filed 2019-05-10
$179.08K
derived: sum of 2 quarters · filed 2019-05-10
$811.20K
10-Q · filed 2019-05-10
2017-12-31$27.02K
10-Q · filed 2019-05-10
$39.77K
10-Q · filed 2019-02-12
2017-09-30$12.75K
10-Q · filed 2019-05-10

Similar stocks

Stock NameCountryMarket CapPE Ratio
Aspire Biopharma Holdings, Inc. (ASBP)United States$0.012B-0.60
ADIAL PHARMACEUTICALS, INC. (ADIL)United States$0.012B
Phio Pharmaceuticals Corp. (PHIO)United States$0.012B-0.92
Tempest Therapeutics, Inc. (TPST)United States$0.013B
Scienture Holdings, Inc. (SCNX)United States$0.012B-0.38
KIORA PHARMACEUTICALS INC (KPRX)United States$0.012B
Dare Bioscience, Inc. (DARE)United States$0.011B
AEON Biopharma, Inc. (AEON)United States$0.013B-0.36
MUSTANG BIO, INC. (MBIO)United States$0.013B
Vistagen Therapeutics, Inc. (VTGN)United States$0.013B-0.14